Novo Nordisk AS (XTER:NOV)
€ 99.51 -3.09 (-3.01%) Market Cap: 442.81 Bil Enterprise Value: 440.41 Bil PE Ratio: 35.07 PB Ratio: 27.45 GF Score: 91/100

Novo Nordisk A/S Investor and Analyst Event at ADA Transcript

Jun 06, 2022 / 12:30AM GMT
Release Date Price: €52.18
Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board

/- -

All right. I believe we're ready to roll. So welcome to the Novo Nordisk R&D event in conjunction with the ADA 2022 here in New Orleans in hot summer June. It's great to see all here, and we have a very nice R&D presentation coming up. And I have to remind you that this event is being broadcasted. And the setup is that we will do a presentation of some 40 minutes or something like that, followed by a Q&A. And then we have a small social event afterwards. So that's kind of the format.

And as usual then, I have to remind you around, especially when we talk about R&D, that there will be a number of forward-looking statements, and the future does not always pan out as we predict in our internal modeling and forecasting, so hereby warned appropriately.

So today, we are a team of 3 from management in Novo Nordisk. So starting with myself, Karsten Knudsen, CFO of Novo Nordisk for a little bit more than 4 years now. With me, I have Martin

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot